EPS for FibroGen, Inc. (FGEN) Expected At $-0.26; La-z-boy (LZB) Sentiment Is 1.02 – EN Digest

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.26 EPS on February, 26.They anticipate $0.01 EPS change or 3.70% from last quarter’s $-0.27 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -48.00% EPS growth. The stock increased 0.47% or $0.26 during the last trading session, reaching $56.04. About 207,258 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 13.72% since February 4, 2018 and is downtrending. It has underperformed by 13.72% the S&P500. Some Historical FGEN News: 31/05/2018 – ASTELLAS PHARMA INC – FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT; 31/05/2018 – ASTELLAS PHARMA INC – SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS; 12/04/2018 – $GLPG moving fast into #IPF Ph3 vs. $FGEN still at a snail’s pace; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic; 09/05/2018 – FibroGen 1Q Rev $31.9M; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY; 12/04/2018 – ARGENTINA IS SAID TO PROBE TRADES OF ANDES FOR INSIDER TRADING; 06/04/2018 – HK Bourse: Announcement From Pacific Andes International Holdings Ltd; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom

La-z-boy Inc (LZB) investors sentiment decreased to 1.02 in Q3 2018. It’s down -0.13, from 1.15 in 2018Q2. The ratio dropped, as 84 investment managers increased or started new equity positions, while 82 reduced and sold their stakes in La-z-boy Inc. The investment managers in our database now hold: 41.66 million shares, down from 41.68 million shares in 2018Q2. Also, the number of investment managers holding La-z-boy Inc in top ten equity positions was flat from 1 to 1 for the same number . Sold All: 18 Reduced: 64 Increased: 51 New Position: 33.

Botty Investors Llc holds 5.19% of its portfolio in La-Z-Boy Incorporated for 604,435 shares. Dean Capital Management owns 58,352 shares or 1.3% of their US portfolio. Moreover, Smith Graham & Co. Investment Advisors Lp has 0.95% invested in the company for 317,162 shares. The New York-based Silvercrest Asset Management Group Llc has invested 0.75% in the stock. Dean Investment Associates Llc, a Ohio-based fund reported 144,385 shares.

Analysts await La-Z-Boy Incorporated (NYSE:LZB) to report earnings on February, 19. They expect $0.55 EPS, up 22.22% or $0.10 from last year’s $0.45 per share. LZB’s profit will be $25.77M for 13.55 P/E if the $0.55 EPS becomes a reality. After $0.48 actual EPS reported by La-Z-Boy Incorporated for the previous quarter, Wall Street now forecasts 14.58% EPS growth.

The stock decreased 0.03% or $0.01 during the last trading session, reaching $29.82. About 101,161 shares traded. La-Z-Boy Incorporated (LZB) has declined 16.50% since February 4, 2018 and is downtrending. It has underperformed by 16.50% the S&P500.

La-Z-Boy Incorporated manufactures, markets, imports, exports, distributes, and retails upholstery furniture products, accessories, and casegoods furniture products in the United States, Canada, and internationally. The company has market cap of $1.40 billion. It operates through Upholstery, Casegoods, and Retail divisions. It has a 16.82 P/E ratio. The Upholstery segment makes and imports upholstered furniture, such as recliners and motion furniture, sofas, loveseats, chairs, sectionals, modulars, ottomans, and sleeper sofas.

Since January 1, 0001, it had 0 insider buys, and 4 sales for $7.42 million activity.

More notable recent La-Z-Boy Incorporated (NYSE:LZB) news were published by: Globenewswire.com which released: “La-Z-Boy Names New General Counsel – GlobeNewswire” on January 08, 2019, also Gurufocus.com with their article: “Tipperary Sales, a La-Z-Boy Home Furnishings & Décor Dealer, Names Jacob Jones Company President – GuruFocus.com” published on January 09, 2019, Benzinga.com published: “La-Z-Boy (NYSE:LZB) Shows Strong Execution, But Has Balanced Risk-Reward, KeyBanc Says In Downgrade – Benzinga” on August 23, 2018. More interesting news about La-Z-Boy Incorporated (NYSE:LZB) were released by: Globenewswire.com and their article: “La-Z-Boy Reports 12% Sales Increase for Second-Quarter – GlobeNewswire” published on November 28, 2018 as well as Globenewswire.com‘s news article titled: “La-Z-Boy Reports Fiscal 2019 First-Quarter Results – GlobeNewswire” with publication date: August 21, 2018.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.76 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Among 2 analysts covering FibroGen (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. FibroGen had 2 analyst reports since October 15, 2018 according to SRatingsIntel. On Monday, October 15 the stock rating was maintained by Leerink Swann with “Outperform”. On Wednesday, December 19 the stock rating was upgraded by Citigroup to “Buy”.